Back to results
US 11,908,588 B2Granted
Systems and methods for genetic analysis of metastases
AssigneeNantOmics, LLC
InventorJohn Zachary Sanborn
Life of this patent
Estimating the term…
Abstract
Contemplated systems and methods use identification and classification of somatic single nucleotide variants found in a primary tumor and metastases to determine phylogeny of the metastases.
Claims15
A method of determining phylogeny of a metastasis and treating a melanoma patient, the method comprising:
- obtaining a plurality of respective nucleic acid sequences from a primary tumor, a first metastasis, a second metastasis, and non-tumor tissue collected from a melanoma patient;
- informationally coupling an analysis engine to a sequence database, wherein the sequence database stores the plurality of respective nucleic acid sequences;
- determining, by the analysis engine, somatic single nucleotide variants (SSNVs) for the primary tumor, the first metastasis, and the second metastasis relative to the nucleic acid sequences from non-tumor tissue of the patient by using an error probability model,
- wherein the error probability model comprises the steps of mapping short reads of the tumor sequences to the reference genome and determining error probability by using a statistical model that incorporates the mapping qualities, error probabilities from raw sequence quality scores, sampling of two haplotypes, and an empirical model for correlated errors at a site;
- filtering, by the analysis engine, the determined SSNVs;
- determining, by the analysis engine, a status for each SSNV with respect to each of the nucleic acid sequences from the primary tumor, the first metastasis, and the second metastasis;
- using, by the analysis engine, the status to classify each SSNV into a class selected form the group consisting of as a fully shared SSNV, a partially shared SSNV, a private SSNV, or an absent SSNV;
- using, by the analysis engine, the classifications of the SSNVs, to calculate a phylogenetic profile for the primary tumor, the first metastasis, and the second metastasis;
- and
- generating a targeted therapy for the melanoma, prepared for administration, wherein the targeted therapy recognizes or binds to the fully shared SSNV, wherein the fully shared SSNV is one that is present in the primary tumor, first metastasis and second metastasis.
7 more elements
A method of determining phylogeny of a metastasis and treating a melanoma patient, the method comprising:
- obtaining a plurality of respective nucleic acid sequences from a primary tumor, a first metastasis, a second metastasis, and non-tumor tissue collected from a melanoma patient;
- informationally coupling an analysis engine to a sequence database, wherein the sequence database stores the plurality of nucleic acid sequences;
- determining, by the analysis engine somatic single nucleotide variants (SSNVs) for the primary tumor, the first metastasis, and the second metastasis relative to the nucleic acid sequences from non-tumor tissue of the patient, wherein the step includes a determination of likelihood for a possible genotype using an error probability model;
- wherein the error probability model comprises the steps of mapping short reads of the tumor sequences to the reference genome and determining error probability by using a statistical model that incorporates the mapping qualities, error probabilities from raw sequence quality scores, sampling of two haplotypes, and an empirical model for correlated errors at a site;
- filtering, by the analysis engine, the determined SSNVs;
- identifying, by the analysis engine, for each of the primary tumor, the first metastasis, and the second metastasis fully shared SSNVs, partially shared SSNVs, private SSNVs, and absent SSNVs;
- calculating, by the analysis engine, a phylogenetic profile for the primary tumor, the first metastasis, and the second metastasis based on the fully shared SSNVs, partially shared SSNVs, private SSNVs, and absent SSNVs;
- and
- generating a targeted therapy for the melanoma, prepared for administration, wherein the targeted therapy recognizes or binds to the fully shared SSNV, wherein the fully shared SSNV is one that is present in the primary tumor, first metastasis and second metastasis.
6 more elements
Dependencies are inferred from the claim text.